All companies
Visit website
Myaderm
OperatingMyaderm, Inc.
Retail · Founded 2016
Revolutionizing pain relief & skin care with cbd
Post-money valuation ⓘ
$24.9M
As of Sep 2022 · from Myaderm Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$26,678
Across 1 round since 2022
Latest share price
$2.00
Myaderm Common Stock 1 offering price
Financials
FY2020–FY2021 · from SEC filings · hover any figure for its source$1.8M
−$1.1M
2020
$1.7M
$383K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
Income statement
Revenue
$1,787,846
$1,748,679
Cost of goods sold
$515,391
$391,166
Gross margin
71%
78%
Net income
-$1,137,224
$382,820
Taxes paid
$418,920
-$77,365
Balance sheet
Cash
$42,856
$137,128
Accounts receivable
$662,280
$548,806
Total assets
$3,057,868
$2,787,567
Short-term debt
$874,582
$196,431
Long-term debt
$1,620,230
$1,645,262
Total liabilities
$2,494,812
$1,841,693
Other
Headcount
—
6
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$24.9M
post-money
Myaderm Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $26.7K / $1.1MInvestors 53Post-money $24.9M
Reg CF annual-report compliance
Delinquent
Filed 0 of 4 annual reports (FY2022–FY2025)
Missing: 2022, 2023, 2024, 2025
53 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001758322Share price $2.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.